# Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib

> **NCT07633626** · — · RECRUITING · sponsor: **Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo** · enrollment: 24 (estimated)

## Conditions studied

- Advanced ALK/ROS1-positive NSCLC
- Carcinoma, Non-Small-Cell Lung (NSCLC)
- Lung Adenocarcinoma
- ALK-positive Non-small Cell Lung Cancer (NSCLC)
- Cognitive Dysfunction
- Depression

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07633626
- **Lead sponsor:** Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-10
- **Primary completion:** 2027-03-10
- **Final completion:** 2027-11-10
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07633626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07633626, "Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07633626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*